ArticleInternational journal of molecular sciences2021
Biological Evaluation and Transcriptomic Analysis of Corylin as an Inhibitor of Osteoclast Differentiation.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Evidence for Potentiation of M-Type Potassium Current by Flavonoid Corylin (3-(2,2-Dimethylchromen-6-yl)-7-hydroxychromen-4-one).Pharmaceuticals (Basel, Switzerland) · 2026Article
- Dissolvable microneedles loaded with denosumab alleviate knee osteoarthritis in rodent and canine models by inhibiting macrophage senescence.Theranostics · 2026Article
- Green ultrasound‑assisted deep eutectic solvent extraction of flavonoid enzyme inhibitors fromJournal of enzyme inhibition and medicinal chemistry · 2025Article
- Corylin ameliorates inflammaging and pyroptosis in diabetic periodontitis: A preliminaryJournal of dental sciences · 2025Article
- Contribution of Osteoblast and Osteoclast Supernatants to Bone Formation: Determination Using a Novel Microfluidic Chip.International journal of molecular sciences · 2024Article
- Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent.Aging · 2024Article
- Targeting bone homeostasis regulation: potential of traditional Chinese medicine flavonoids in the treatment of osteoporosis.Frontiers in pharmacology · 2024Review
- Osteoclastogenesis and Osteogenesis.International journal of molecular sciences · 2022Article
- Modulation of Gut Microbiota Combined with Upregulation of Intestinal Tight Junction Explains Anti-Inflammatory Effect of Corylin on Colitis-Associated Cancer in Mice.International journal of molecular sciences · 2022Article
- Corylin Ameliorates LPS-Induced Acute Lung Injury via Suppressing the MAPKs and IL-6/STAT3 Signaling Pathways.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
Corylin, a flavonoid isolated from the fruit of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.